Identifying and managing diabetes and weight loss therapies earns AMCP platinum award

Home Newsroom Custom Content Publications Drug Approvals Drug Approvals Monthly Update: September 2024 1. ADvocate 1 and 2 trials: https://pubmed.ncbi.nlm.nih.gov/36920778/ 2. ADhere trial:...

Read Drug Approval Update Specialty New drugs 06/06/2024 Rytelo™ (imetelstat) The FDA approved the first-in-class oligonucleotide telomerase inhibitor, Rytelo, for the treatment of adults with low-...

Specialty New drugs 3/18/2024 Lenmeldy™ (atidarsagene autotemcel) Lenmeldy is an autologous hematopoietic stem cell-based gene therapy by Orchard Therapeutics, which was FDA approved for the...

Read Drug Approval Update Specialty New drugs 04/22/2024 Anktiva® (nogapendekin alfa inbakicept-pmln) The FDA approved Anktiva for use in combination with Bacillus Calmette-Guérin (BCG) for the...

Editor-In-Chief: Maryam Tabatabai, PharmD Executive Editor: Anna Schreck Bird, PharmD Deputy Editors: Erik Hamel, PharmD; Olivia Pane, PharmD, CDCES A retrospective propensity score-matched cohort...

Drug Approvals Monthly Update: August 2024 This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals provides a review of newly approved specialty drugs, new...

Clinical deep dive Disease state overview SMA is a rare, debilitating, hereditary disease characterized by progressive motor function decline and muscular atrophy. Most commonly, SMA results from a...

Zolgensma, which was FDA approved in May 2019, is administered as an intravenous (IV) infusion, with dosing based on patient weight, in pediatric patients under 2 years of age with SMA caused by...

Generic Name Brand Name Manufacturer Indication(s) Route of Administration Month Approved* aprocitentan Tryvio® Idosia Difficult-to-control or resistant hypertension Oral March budesonide Eohilia™...